TLR5 and neoplasm: Our findings suggest that the use of an appropriate combination of CAR133 with the immune regulatory factor TLR5 agonist, CBLB502, enhanced the anti-tumor potential of NK92 cells in coordination with the mobilization of tumor-reactive endogenous immune cells (Figure 8).